Effect of apigetrin in pseudo-SARS-CoV-2-induced inflammatory and pulmonary fibrosis in vitro model

Effect of apigetrin in pseudo-SARS-CoV-2-induced inflammatory and pulmonary fibrosis in vitro model | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Effect of apigetrin in pseudo-SARS-CoV-2-induced inflammatory and pulmonary fibrosis in vitro model Hengmin Han, Jung-Eun Kim, Hyo-Jeong Lee This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4131121/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract SARS-CoV-2 has become a global public health problem. Acute respiratory distress syndrome (ARDS) is the leading cause of death due to the SARS-CoV-2 infection. Pulmonary fibrosis (PF) is a severe and frequently reported COVID-19 sequela. In this study, an in vitro model of ARDS and PF caused by SARS-CoV-2 was established in MH-S, THP-1, and MRC-5 cells using pseudo-SARS-CoV-2 (PSCV). Expression of proinflammatory cytokines (IL-6, IL-1β, and TNF-α) and HIF-1α was increased in PSCV-infected MH-S and THP-1 cells, ARDS model, consistent with other profiling data in SARS-CoV-2-infected patients have been reported. Hypoxia-inducible factor-1 alpha (HIF-1α) siRNA and cobalt chloride were tested using this in vitro model. Furthermore, apigetrin, a glycoside bioactive dietary flavonoid derived from several plants, including Crataegus pinnatifida, which is reported to be a HIF-1α inhibitor, was tested in this in vitro model [ 1 ]. Apigetrin significantly reduced the increased inflammatory cytokine (IL-6, IL-1β, and TNF-α) expression and secretion by PSCV in MH-S and THP-1 cells. Apigetrin inhibited the binding of the SARS-CoV-2 spike protein RBD to the ACE2 protein. An in vitro model of PF induced by SARS-CoV-2 was produced using a conditioned medium of THP-1 and MH-S cells that were PSCV-infected (CMPSCV) into MRC-5 cells. In a PF model, CMPSCV treatment of THP-1 and MH-S cells increased cell growth, migration, and collagen synthesis in MRC-5 cells. In contrast, apigetrin suppressed the increase in cell growth, migration, and collagen synthesis induced by CMPSCV in THP-1 and MH-S MRC-5 cells. Also, compared to control, fibrosis-related proteins (CTGF, COLA1, α-SMA, and HIF-1α) levels were over two-fold higher in CMPSV-treated MRC-5 cells. Apigetrin decreased protein levels in CMPSCV-treated MRC-5 cells. Thus, our data suggest that hypoxia-inducible factor-1 alpha (HIF-1α) might be a novel target for SARS-CoV-2 sequela therapies and apigetrin, representative of HIF-1alpha inhibitor, exerts anti-inflammatory and PF effects in PSCV-treated MH-S, THP-1, and CMPVSC-treated MRC-5 cells. These findings indicate that HIF-1α inhibition and apigetrin would have a potential value in controlling SARS-CoV-2-related diseases. SARS-CoV-2 Acute respiratory distress syndrome (ARDS) Pulmonary fibrosis (PF) Hypoxia-inducible factor-1α (HIF-1α) Apigetrin Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 1. Introduction Covid-19 is an infectious coronavirus disease caused by SARS-CoV-2 virus. Most SARS-CoV-2-infected individuals experience mild-to-moderate illness and recover without special treatment [ 2 ]. However, patients with advanced age, cardiovascular disease, diabetes, obesity, chronic respiratory disease, and cancer are more likely to develop severe illnesses and require medical attention. Recently, a variant mutation type of SARS-CoV-2 has emerged. SARS-CoV-2 and its variants cause short- or long-term lung complications such as pneumonia, acute respiratory distress syndrome (ARDS), sepsis, and bronchitis. Furthermore, SARS-CoV-2 leaves sequelae. The post-acute sequelae of COVID-19 (PASC) include interstitial lung disease (ILD) and pulmonary fibrosis (PF). Post-COVID-19 ILD and PF respiratory symptoms include a chronic dry cough, fatigue, and dyspnea. Ap-proximately 44.9% of COVID-19 survivors appeared to have developed PF. Factors related to COVID-19 severity were significantly associated with post-COVID-19 PF (PCPF) development. COVID-19 has the potential to elicit a cytokine storm in pulmonary tissues, marked by immune system overactivation and unregulated cytokine release [ 3 ] Cytokine storms can lead to a severe clinical complication called ARDS. ARDS is triggered by an exaggerated immune response rather than viral load [ 4 ]. Studies have found that extraordinarily high proinflammatory cytokine levels in SARS cytokine release syndrome, such as TNF-α, IL-6, IL-8, IL-1β, IL-12, IL-17, IFN-γ, IP10, and MCP1, are the probable causes and clinical outcomes of this phenomenon in severe COVID-19 cases and contribute to COVID-19 pathogenesis and related complications, including pulmonary inflammation and extensive lung damage [ 5 , 6 ]. Several studies showed that the upregulation and participation of hypoxia-inducible factor-1α (HIF-1α) relate to inflammation, immunometabolism, and TLR in bronchoalveolar cells of critically severe COVID-19 patients [ 7 ]. Also, high HIF-1α levels were detected in peripheral blood monocytes of COVID-19 patients and infected cells [ 8 ]. The HIF-1α acts as a key regulator in physiological functions including metabolism, cell proliferation, and angiogenesis [ 9 – 11 ]. HIF-1α is also an important activator in glycolysis and inflammatory response, which implies the effects of HIF-1α on the pathogenesis of COVID-19 [ 12 , 13 ]. Recently, many studies have reported the development of SARS-CoV-2 vaccines and drugs. However, most targeted therapeutics against SARS-CoV-2 focus on vaccines or blockers of entry into cells to prevent SARS-CoV-2 infection. Supportive therapeutic interventions and antiviral agents with limited efficacy are required to reduce the COVID-19 outbreak and mitigate its symptoms [ 14 , 15 ]. Although much research has focused on developing vaccines and antiviral therapies to prevent or treat SARS-CoV-2 infection, studying their long-term effects and post-infection complications is crucial. Few studies have targeted inflammation (immunomodulatory properties). Few studies have investigated targeted therapeutic agents for post-SARS-CoV-2-related lung diseases. Furthermore, most SARS-CoV-2 experiments are difficult to perform in a laboratory without biosafety level 3 (BSL-3) permission. Therefore, a reliable, rapid, and convenient in vitro model of SARS-CoV-2-related lung disease that can be handled in a BSL-2 laboratory is essential for screening and evaluating therapeutic agents against SARS-CoV-2 infection. Therefore, based on SARS-CoV-2 clinical data reported, we established in vitro models of ARDS and PF using pseudotyped SARS-CoV-2 virus, and inflammation and PF-related markers were assessed in this study. Natural products have received considerable attention as potential therapeutic options. Flavonoids, naturally occurring polyphenolic compounds in fruits and vegetables, have received significant attention owing to their anticancer, anti-inflammatory, antioxidant, antibacterial, fungal, and viral properties. Therefore, flavonoid-rich flavonoids and plants are considered applicable agents for treating COVID-19, and their potentially beneficial role is currently a widely discussed topic. Apigetrin, apigenin 7-O-glucoside, and cosmosin are flavonoid glycosides commonly found in natural sources. Apigenin has various beneficial properties including antioxidant, anti-obesity, anticancer, and anti-inflammatory effects [ 16 – 20 ]. We have determined that apigetrin has an anti-cancer effect by inhibiting HIF-1α [ 21 ]. Therefore, based on the reported data on apigetrin, we evaluated the effect of apigetrin on SARS-CoV-2 complications mimicking in vitro models. 2. Materials and Methods 2.1. Test Chemical Apigetrin (M.W = 432.38 g/mol, purity ≥ 97% as determined through HPLC) was purchased from Sigma-Aldrich (Cat: 44692, St. Louis, MO, USA). HIF-1α siRNA was purchased from Santa Cruz (Cat: sc-35561, Dallas, TX, USA), and CoCl 2 was purchased from Sigma-Aldrich (Cat: C8661, St. Louis, MO, USA). 2.2. Cell Culture MH-S (Cat: CRL-2019, American Type Culture Collection (ATCC), Manassas, VA, USA) and THP-1 cells (Cat: TIB-202, ATCC, Manassas, VA, USA) were cultured in RPMI 1640 (Cat: LM 011 − 01, WELGENE, Daegu, Korea) medium supplemented with 10% fetal bovine serum (Cat: S101-07, WELGENE, Daegu, Korea) and 1% antibiotics (Cat: LS203-01, WELGENE, Daegu, Korea). Lenti-XTM 293T (Cat: 632180, Takara Bio Inc., Shiga, Japan) and MRC-5 (Cat: 10171, KCLB, Seoul, Korea) cells were cultured in DMEM (Cat: LM-001-05, WELGENE, Daegu, Korea) medium supplemented with 10% FBS and 1% antibiotics. All the cells were cultured in a humidified atmosphere at 37°C containing 5% CO 2 to maintain the required physiological conditions. 2.3. SARS-CoV-2 Pseudo-Typed Lentivirus Lenti-X 293T cells (5 × 10 6 ) were seeded/10 cm plate in complete medium for 24 h. The Lenti-X™ SARS-CoV-2 Packaging Single Shots (Takara, Vancouver, Canada) were used to cultivate the SARS-CoV-2 pseudotyped lentivirus. After 4 h treating Lenti-X™ SARS-CoV-2 Packaging Single Shots, 6 mL of fresh complete growth medium was added and incubated at 37°C, 5% CO 2 for an additional 48 h. 5X107 pseudo-SARS-CoV-2 were used to infect MH-S and THP-1 cells. 2.4. Immunofluorescence MH-S and THP-1 cells (1 × 10 4 cells) were seeded in confocal dishes (Cat: 210350; SPL, Pocheon, Korea). After, the cells were incubated for 24 h at 37°C containing 5% CO 2 , treated with PSCV and apigetrin (10 µM) for 24 h, then were fixed in 100% methanol (chilled at -20°C) at room temperature for 5 min. The fixed cells were exposed to the di-luted Spike 1 (Cat: 99423, Cell Signaling, Danvers, MA, USA) antibody in 1% BSA in PBST in a humidified chamber overnight at 4°C. Then, cells were incubated with the goat anti-rabbit IgG (Alexa Fluor® 488) (Cat: ab150077, Abcam, Cambridge, UK) in 1% BSA for 1 h at room temperature in the dark. The reacted cells were incubated with VECTASHIELD® antifade mounting medium with DAPI (Cat: H-1200-10, Vector Laboratories, Burlingame, CA, USA) for 3 min. Images were captured randomly and each slide was imaged using a fluorescence microscope (Nikon, Tokyo, Japan). 2.5. SARS-CoV-2 Binding Assay A SARS-CoV-2 inhibitor screening kit (Cat: EP-105, ACROBIOSYSTEMS, Newark, DE 19711, USA) was used to test the ability of apigetrin to bind to the SARS-CoV-2 S protein RBD. SARS-CoV-2 S protein RBD stock solution (100 µg/mL) was diluted to 0.5 µg/mL with a coating buffer to make the SARS-CoV-2 S protein RBD working solution. Biotinylated human ACE2 stock solution (100 µg/mL) was diluted to 0.12 µg/mL with a dilution buffer to make a biotinylated human ACE2 working solution. A total of 50 uL of apigetrin (10 µM) was added, and the plate was sealed with a microplate sealing film and incubated for 1 h. Streptavidin-HRP stock solution (50 µg/mL) was diluted to 0.1 µg/mL with a dilution buffer and incubated for 1 h. Then, 100 µL of Streptavidin-HRP working solution was added and incubated for 1 h. TMB Substrate Working Solution (200 µL) was added to each well and incubated for 20 min. Then, 50 µL of stop solution was added and tapped gently for 3 min. The absorbance was measured at 450 nm using a UV microplate spectrophotometer. 2.6. Western Blot Analysis Protein samples were obtained by lysing cells in radioimmunoprecipitation assay (RIPA) buffer, which comprised 50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 M EDTA, 1 mM Na 3 VO 4 , 1 mM NaF, and protease inhibitor cocktail (Cat: 89900, 87786, 78420, Thermo, Waltham, MA, USA). Protein concentration was determined using the Bio-Rad DC Protein Assay Kit II (Cat: 500 − 0113, 500 − 0114, 500 − 0115, Bio-Rad, Hercules, CA, USA). The quantified protein samples were loaded onto 8–15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred onto a Hybond transfer membrane (Cat: 10600002, 10600001, Amersham Pharmacia, Piscataway, NJ, USA) using a transfer system at 250 mA for 2 h. Non-specific binding on membranes was blocked in fresh 5% non-fat dry milk (Cat: DI-232100, BD, Franklin Lakes, NJ, USA), after which the membranes were incubated with primary antibodies against IL-6 (ratio 1:2000, Cat: SC-28343, Santa Cruz, Dallas, TX, USA), Spike1 (ratio 1:1000, Cat: 99423, Cell Signaling, Danvers, MA, USA), IL-1β (ratio 1:1000, Cat: SC-12742, Santa Cruz, Dallas, TX, USA), TNF-α (ratio 1:1000, Cat: SC-52746, Santa Cruz, Dallas, TX, USA), CTGF (ratio 1:1000, Cat: SC-101586, Santa Cruz, Dallas, TX, USA), COLA1 (ratio 1:1000, Cat: ab6308, Abcam, Cambridge, UK), α-SMA (ratio 1:1000, Cat: SC-53015, Santa Cruz, Dallas, TX, USA), HIF-1α (ratio 1:500, Cat: NB100-105, NOVUS, Littleton, CO, USA), and β-actin (ratio 1:10000, Cat: A5316, Sigma-Aldrich, St. Louis, MO, USA) overnight at 4°C. Mem-branes were incubated with horseradish peroxidase (HRP)-conjugated anti-mouse (ratio 1:10000, Cat: 115-035-003; Jackson, West Grove, PA, USA) or anti-rabbit secondary anti-bodies (ratio 1:10000, Cat: 111-035-003, Jackson, West Grove, PA, USA). An enhanced chemiluminescence (ECL) system (Cat: RPN2209; Amersham Pharmacia, Piscataway, NJ, USA) was used for the protein expression analysis. Densitometric data were obtained by quantifying each protein band using ImageJ 1.53k (National Institutes of Health, Bethesda, MD, USA). Protein levels were quantified from the duplicate analyses of each sample. Protein levels of interest were normalized to β-actin. 2.7. SARS-CoV-2 Cytokines Secretion Quantification MH-S and THP-1 cells (1 × 10 6 ) were seeded in a 60 mm cell culture dish and incubated for 24 h. The cells were treated with or without PSCV and apigetrin (10 µM) for 24 h, then the supernatant was harvested. The secretion of TNF-α, IL-6, and IL-1β by MH-S or THP-1 cells was measured using ELISA with a paired set of antibodies and HRP-labeled streptavidin (Cloud-Clone, Cat: SEA079Hu, SEA133Hu, SEA563Hu, SEA563Mu, SEA133Mu, SEA079Mu, Katy, TX, USA). The optical density was measured at 450 nm using a microplate reader (Sunrise RC, Tecan, Mannedorf, Switzerland). 2.8. Cell Proliferation Assay MRC-5 cells (1 × 10 4 ) were seeded in 96-well plates (Cat: 30096; SPL, Pocheon, Korea) and incubated for 24 h. The cells were treated with or without apigetrin (10 µM) in CMP-SCV for 24 h. Cell viability was evaluated using a CELLOMAXTM viability kit (Cat: CM-VA2500, Precaregene, Hanam, Korea). CELLOMAXTM reagent (10 µL) was added to each well and was incubated in the dark. The optical density was measured at 450 nm using a microplate reader (Sunrise RC, Tecan, Mannedorf, Switzerland). 2.9. Migration Assay MRC-5 cells (5 × 10 4 ) were seeded into a Cell Culture Insert (Cat: 36224, SPL, Pocheon, Korea) at a density of 2.5 × 10 5 /mL in a serum-free medium. 700 µL of CMPSCV or CTP-SCV medium (with serum) treated with or without apigetrin in the lower chamber. Trans-fer the insert into the lower chamber. The plates were incubated for 24 h at 37°C containing 5% CO 2 . The medium was removed, and the cells were washed with PBS. Cells were fixed with 3.5% formaldehyde (in PBS) at room temperature for 2 min and permeabilized with methanol at room temperature for 20 min. The cells were then stained with crystal violet at room temperature for 15 min. Nonmigratory cells were scraped off using cotton swabs. Images were captured under a light microscope (Nikon, Tokyo, Japan). 2.10. Statistical Analysis The data presented in this study are expressed as mean ± standard deviation (S.D.) and were obtained from three replicates for each experiment. Analysis of variance was used to assess the significance of differences between groups. A p-value less than 0.05 was considered statistically p < 0.05. Significance was evaluated using the Sigma Plot software. ( * p < 0.05, ** p < 0.01, *** p < 0.001). Data were analyzed by one-way ANOVA, followed by Tukey’s studentized range test using the GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA). Means with different letters are significantly different between the groups. 3. Results 3.1. In vitro ARDS model using PSCV in MH-S and THP-1 cells shows increased proinflammatory cytokines and HIF-1α Lipopolysaccharide-treated MH-S cells were used as an in vitro model of ARDS. We modified this model to establish an in vitro model that mimics ARDS caused by SARS-CoV-2. An in vitro model, a SARS-CoV-2 ARDS mimic, was produced by treating THP-1 and MH-S cells with PSCV instead of LPS. We checked the proinflammatory cytokines and HIF-1α levels that have been reported as highly expressed in SARS-CoV-2 patients. Spike protein-1 was used to confirm the infection of cells with PSCV. As shown in Figures 1A and B, IL-6, IL-1β, TNF-α, and HIF-1α showed over 1.5-fold higher expression than PSCV-non-treated cells in MH-S and THP-1 cells. Especially, HIF-1α expression indicated 2.8- and 9.2-fold higher expression than PSCV-non-treated cells in, respectively, MH-S and THP-1 cells. 3.2. In vitro PF model using a conditioned medium of PSCV-treated MH-S or THP-1 cells (CMPSV) in MRC-5 cells shows increased expression of CTGF, COLA1, α-SMA, and HIF-1α PF is frequently reported as a COVID-19 sequela of [22-25]. As elevated cytokine levels regulate the initiation and progression of fibrosis and remodeling, an in vitro model mimicking SARS-CoV-2 PF was produced by treating MRC-5 cells with CMPSCV. CMPSCV is a culture medium obtained after a 48-hour culture of culturing PSCV-infected MH-S or THP-1 cells. The in vitro PF model was established by culturing MRC-5 cells in the two types of CMPSCV for 24 h. If CMPSV is involved in MRC-5 differentiation to change fibroblast to myofibroblast, we expected MRC-5 cells to increase CTGF, COLA-1, and α-SMA. As shown in Figure 1C and D, CTGF, COLA1, α-SMA, and HIF-1α expression significantly increased in CMPSV of MHS or THP-1 cells compared to the control group, without CMPSV. 3.3. HIF-1α knockdown ameliorates inflammation induced by PSCV infection in MH-S and THP-1 cells and decreases increased CTGF, COLA1, and α-SMA in CPMSCV-exposure MRC-5 cells To confirm the role of HIF-1α in the PSCV-induced inflammation in MH-S and THP-1 cells, HIF-1α knockdown experiments were performed. HIF-1α protein 6.9 and 6.64 folds higher expressed in PSCV-infected MH-S and THP-1 cells compared with non-infected MH-S and THP-1 cells, while HIF-1α siRNA blocked the PSCV-induced HIF-1α protein expression in MH-S and THP-1 cells. Also, HIF-1α siRNA suppressed inflammatory proteins IL-6, IL-1β, and TNF-α levels increased in PSCV-infected MH-S and THP-1 cells (Figure 2A and B). Spike protein was confirmed as a PSCV infection marker. Spike protein showed strong expression in PSCV-infected MH-S cells and THP-1 cells, while the spike protein was decreased by treating HIF-1α siRNA to PSCV-infected MH-S and THP-1 cells (Figure 2A and B). In contrast, cobalt chloride (CoCl 2 ), a hypoxia mimic and inhibitor of HIF-1α degradation, induced inflammatory cytokines in the PSCV-exposure THP-1 cells. In PSCV-treated MH-S cells, CoCl 2 maintained the levels of cytokines that were increased by PSCV (Figure 2C and D). HIF-1α siRNA decreased increased CTGF, COLA1, α-SMA, and HIF-1α in CPMSCV-cultured MRC-5 cells (Figure 2E and F). 3.4. Apigetrin obstructs entering SARS-CoV-2 into the cells. The initial attachment of SARS-CoV-2 to cells involves specific binding between the viral spike (S) glycoprotein and the cellular receptor ACE2. To evaluate whether apigetrin interferes with the formation of the S-ACE2 complex, a SARS-CoV-2 S-ACE2 binding ELISA kit was used. Apigetrin displayed 34% blocking activity between the binding spike S RBD: ACE2 receptor (Figure. 3A). Additionally, we checked the spike protein in the cells after infection with PSCV to MH-S and THP-1 cells. As shown in Figure 1B and C, the spike protein was highly expressed in PSCV-infected MH-S and THP-1 cells. Spike protein expression decreased in PSCV-infected MH-S and THP-1 cells treated with apigetrin. The spike protein expression of apigetrin was reduced by 3.3 and 2.8 folds, respectively, compared with the PSCV-treated MH-S and THP-1 cells (Figure 3A). 3.5. Apigetrin inhibited the inflammatory effect induced by PSCV infection in MHS and THP-1 cells. PSCV-infected MH-S or THP-1 cells showed an increase over two-fold in inflammatory relative cytokines (IL-6, IL-1β, and TNF-α) and spike protein levels compared with non-infected cells. (Figure. 4A and B). In contrast, apigetrin attenuated the PSCV-induced increase in inflammatory cytokines and spike protein levels (Figure. 4A and B). IL-6, IL-1β, and TNF-α secretion levels increased by PSCV in MH-S and THP-1 cells (Figure. 4C-H). The amount showed 129.5 pg/ml for IL-6, 119 pg/ml for IL-1β, and 201 pg/ml for TNF-α increasing 34.54, 14.4, and 6.19 folds respectively, compared with the control group (3.75, 8.23, and 32.3 pg/ml) in MH-S cells (Figure. 4C, D, and E). Apigetrin reduced the increased IL-6, IL-1β, and TNF-α secretion levels up to 22.5, 47.3, and 68.2%, respectively (Figure 4C, D, and E). In the case of THP-1 cells, the increased amount indicated 93.9, 77.29, and 156 pg/ml for IL-6, IL-1β, and TNF-α, rising 14, 6.08, and 5.71 folds by PSCV, respectively, compared with the control group (6.7, 12.7, and 27.3 pg/ml) (Figure. 4F, G, and H). Similar to MH-S cell data, apigetrin decreased the increased secretion levels of cytokines up to 71, 56.6, and 67.2% for IL6, IL-1β, and TNF-α, respectively (Figure 4F, G, and H). 3.6. Apigetrin attenuated MRC-5 cell proliferation, migration, and expression of CTGF, COLA1, α-SMA, and HIF-1α induced by conditioned medium from PSCV-treated MH-S or THP-1 cells (CMPSCV). The effect of apigetrin on PSCV-induced PF was evaluated in CMPSCV-induced MRC-5 cells. Apigetrin reduced the MRC-5 cell proliferation by 18% CMPSCV of MH-S and THP-1 cells enhanced (Figure. 5A and D). Transwells were used to assess the dynamic fibroblast migration in PF. CMPSCV of MH-S or THP-1 cells increased MRC-5 cell migration by 88 and 87%, respectively, compared to non-treated cells (Figure. 5B and E). The increase in MRC-5 cell motility by CMPSCV was suppressed by apigetrin by 65% and 58%, respectively. Apigetrin significantly decreased the increased CTGF, COLA1, α-SMA, and HIF-1α expression by CMPSCV (Figure 5C and F). Picro Sirius red staining was used to assess collagen expression and observe the differentiated phenotype of MRC-5 cells in response to CMPSV. As shown in Figure. 5B and E, CMPSCV in MH-S or THP-1 cells induced long and stiff-type cells and darker MRC-5 cells. Apigetrin induced a shorter and lighter cell morphology than CMPSCV-induced MRC-5 cells (Figure 5B and E). 4. Discussion In this study, we focused on SARS-CoV-2 post-infection complications and established in vitro models to mimic SARS-CoV-2 infection-related complications. Many studies have reported on the development of SARS-CoV-2 vaccines and drugs that block entry into cells to prevent SARS-CoV-2 infection. According to recently reported clinical data, ACE2 inhibitors and angiotensin receptor blockers (ARBs), the leading SARS-CoV-2 treatments, have not improved clinical outcomes in adult patients with severe COVID-19 and may even worsen them [ 26 ]. The renin-angiotensin system (RAS) relates to SARS-CoV-2 infection, ARDS, pulmonary hypertension, and PF [ 27 , 28 ] RAS system comprises two pathways. One is the angiotensin II (Ang II) generation from angiotensinogen by the enzymes renin and ACE. Ang II binds to the angiotensin type 1 receptor (AT1R) to cause tissue in-jury such as pulmonary hypertension and fibrosis. Another pathway involves the degradation of Ang II to angiotensin 1–7 by the enzyme ACE2, which protects against tissue damage. Therefore, ACE2 plays a counterregulatory role in inhibiting the RAS by removing Ang II. ACE2 has been reported to prevent the development of severe acute respiratory syndrome in SARS-CoV infection [ 29 ] and protect against severe acute lung failure [ 30 ], it has been reported that ACE2 plays a functional receptor on cell surfaces through which SARS-CoV-2 enters host cells [ 31 , 32 ]. In summary, ACE2 is a double-edged sword. There-fore, these targeted inhibitors appear to be suitable for the early or preventive treatment of SARS-CoV-2. ARDS and PF are serious SARS-CoV-2 infection complications. Investigating immunomodulatory therapies is essential, as an overactive immune response (cytokine storm) has been implicated in severe COVID-19 cases. Targeting inflammation and immune responses may help manage post-SARS-CoV-2 complications. To date, the well-known drugs for SARS-CoV-2 immune hyperactivity include tyrosine kinase inhibitors of JAK-STAT signaling and glucocorticoids. Although dexamethasone and methylprednisolone are effective glucocorticoids in reducing the severity of COVID-19 and associated comorbidities such as chronic obstructive pulmonary diseases [ 33 ], these glucocorticoid drugs represent a double-edged sword in COVID-19 therapy. The long-term use of high-dose glucocorticoids causes numerous side effects, such as fluid retention, weight gain, and hyperglycemia [ 34 ]. JAK inhibitors have been clinically used to treat several inflammatory and autoimmune diseases [ 35 , 36 ]. Therefore, JAK inhibitors have been proposed as pharmacological therapies for COVID-19. Tofacitinib, imatinib, and baricitinib exerted clinical benefits in hospitalized patients with COVID-19; however, further studies are required to validate these findings. Immunological dysregulation, also known as the “cytokine storm” by SARS-CoV-2, may be a significant contributor to multiorgan dysfunction [ 37 , 38 ]. Many cytokines have been reported at elevated levels in COVID-19 cases, including IL1-β, IL-6, IL-7, IL-8, TGF-β and TNF-α. Elevated pro-inflammatory cytokines contribute to COVID-19-related complications such as ARDS or PF, mediating the initiation and progression of fibrosis and remodeling [ 39 , 40 ]. Based on these studies, we generated in vitro ARDS and PF models to mimic SARS-CoV-2 complications using pseudo-SARS-CoV-2 in MH-S, THP-1, and MRC-5 cells. Therefore, developing reliable and convenient in vitro models is a valuable approach. These models enable researchers to study disease mechanisms and test potential therapeutic agents in a controlled environment. Using pseudotyped SARS-CoV-2 can help simulate viral infections without the need for a high-containment BSL-3 laboratory, making it more accessible for research. To ensure that our in vitro model closely mimics the clinical aspects of post-SARS-CoV-2 complications, we checked the proinflammatory cytokines, PF-related markers, and HIF-1α levels that have been reported as highly expressed in SARS-CoV-2 patients in PSCV- exposure MH-S and THP-1 cells or CPMSCV-cultured MRC-5 cells. As shown in Fig. 1 A and B, IL-6, IL-1β, TNF-α, and HIF-1α showed higher expression than PSCV-non-treated cells in MH-S and THP-1 cells. A conditioned medium of PSCV-treated MH-S or THP-1 cells (CMPSV) in MRC-5 cells shows increased CTGF, COLA1, α-SMA, and HIF-1α expressions in Figs. 1 C and D. HIF-1α is recognized as a significant activator in glycolysis and is also implicated in inflammatory responses. This suggests that HIF-1α may play a role in the pathogenesis of COVID-19 [ 12 , 13 ]. A recent paper has reported that the HIF-1α mRNA level is much higher in PBMCs of COVID-19 inflammatory patients related to healthy individuals [ 8 ]. Also, the contribution of hypoxia and HIF-1α to the development of interstitial PF as well as PF caused by SARS-CoV-2 is already known [ 41 – 44 ]. Consistent with other reported COVID-19 clinical data, HIF-1α levels increased in PSCV-infected MH-S and THP-1 cells, as well as in CMPSV-stimulated MRC-5 cells (Fig. 1 ). In contrast, HIF-1α knockdown was shown to ameliorate inflammation induced by PSCV infection in MH-S and THP-1 cells and decrease increased CTGF, COLA1, and α-SMA in CPMSCV-exposure MRC-5 cells (Fig. 2 A, B, E, and F). Cobalt chloride (CoCl 2 ), a hypoxia mimic, increased or maintained the cytokine levels induced by PSCV in MH-S and THP-1 cells (Fig. 2 C and D). On the contrary, recently, starting with epidemiological reports for lower COVID-19 incidence in populations living at high altitudes, a few studies supporting the epidemiological reports interestingly showed that an association of the rs11549465 variant of HIF-α with COVID-19 susceptibility was recently discovered [ 45 ] and hypoxic and pharmaco-logical drug of HIF inhibit the infection of lung cells by SARS-CoV-2 by reducing ACE2 viral receptor expression [ 46 ]. However, while these studies are sufficient to help us understand the molecular mechanisms behind the lower incidence of COVID-19 in high-altitude populations, they do not help explain “happy hypoxia,” a pathophysiological phenomenon in which hypoxia increases a patient’s risk of developing a severe form of COVID-19 [ 47 ]. Methods for targeting ACE2 can induce the possible dysfunction of signals when ACE2 is reduced, makes Ang(1–7) no longer synthesized, and AngII accumulates and binds AT1R, leading to HIF-1α causing tissue injury [ 48 , 49 ]. This is also why SARS-CoV-2 binds to ACE2, allowing it to enter cells and cause more severe disease. Furthermore, in the recently reported study by Peter A.C. Wing et al., hypoxia and FG-4592 increased ACE, but the expression of mRNA for HIF-1alpha, a known hypoxia marker, was reduced in these treated cells than in normoxia, 18% O 2 levels [ 46 ]. Unlike the recently reported study by Peter A.C. Wing et al., it has been reported that hypoxia increases ACE, ACE2, and HIF-1α expression in pulmonary artery smooth muscle cells (PASMCs) [ 27 ] and pulmonary artery adventitial fibroblasts (FBPA) [ 50 ], and HIF-1siRNA decreases ACE expression and keeps ACE2 expression in normoxic-PASMCs [ 27 ]. CoCl2, a hypoxia mimic, maintained or induced spike protein expression in PSCV-stimulated MH-S and THP-1 cells (Fig. 2 C and D). However, HIF-1 siRNA reduces spike protein expression in PSC-stimulated MH-S and THP-1 cells (Fig. 2 A and B). In this study, the effects of apigetrin were evaluated using the SARS-CoV-2 complication mimic in vitro model. First, apigetrin was shown to block the activity between the binding spike S RBD and ACE2 receptor and to decrease spike protein expression (Figure. 3A and B). These results in apigetrin attenuated increase of inflammatory cytokine (IL-6, IL-1β, and TNF-α) levels on cytosol, and secretion by PSCV in MH-S and THP-1 cells (Figure. 4). Consistent with our data, apigetrin has been reported to lower TNF-α, IL-1β, and IL-6 production and mRNA expression in LPS-stimulated various cells [ 16 , 17 , 51 ] and in mice with acute otitis media [ 19 ]. Similarly to our model, it has been reported that apigetrin inhibits IL-1α and TGF-β production induced by recombinant spike protein of SARS-CoV-2-stimulated RAW 264.7 cells [ 52 ]. Furthermore, apigetrin has been reported to possess potential inhibitory activity against SARS-CoV-2 3-chymotrypsin-like protease (main protease, Mpro) controlling this COVID-19 virus replication and is essential for its life cycle, according to computational analysis, including molecular docking and pharmacokinetic studies [ 53 ]. In this study, apigetrin is shown to attenuate MRC-5 cell proliferation, migration, expression of CTGF, COLA1, α-SMA, and HIF-1α induced by conditioned medium from PSCV-treated MH-S or THP-1 cells (CMPSCV) (Figure. 5). 5. Conclusions In summary, in this study, we evaluated the feasibility of an in vitro model of SARS-CoV-2 sequelae mimicking and used it to identify molecular mechanisms for HIF-1α targeting in SARS-CoV-2-associated diseases. Furthermore, apigetrin, a candidate drug for treating SARS-CoV-2 complications, was evaluated in this in vitro model. The PSCV particles treated MH-S and THP-1 cells showed increased expression of proinflammatory cytokines (IL-6, IL-1β, and TNF-α) and HIF-1α, consistent with other profiling data in SARS-CoV-2-infected patients have been reported. HIF-1α knockdown was used to determine the role of HIF-1α in this model, with HIF-1α knockdown decreasing increased proinflammatory cytokines levels and fibrosis-related protein levels in PSCV-stimulated MH-S and THP-1 cells and CMPSCV-cultured MRC-5 cells. Apigetrin inhibits the binding of the SARS-CoV-2 spike protein RBD to ACE2 SARS. Increased proinflammatory cytokines, HIF-1α, and spike protein levels were decreased by apigetrin in the SARS-CoV-2 ARDS mimic in vitro model. Apigetrin suppressed the increase of cell growth, migration, collagen synthesis, and fibrosis-regulatory proteins (CTGF, COLA1, α-SMA, and HIF-1α) in the PF model, CMPSCV-cultured MRC-5 cells. Thus, our data support that HIF-1α might be a novel target for SARS-CoV-2 sequela therapies, and apigetrin, a representative HIF-1α inhibitor, would have a potential value in regulating SARS-CoV-2 related diseases. Declarations Acknowledgements. Not applicable. Funding This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT) (No. NRF-2021R1A2C2009095) Conflict of interest/Competing interests The authors declare no conflict or competing interest. Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Data availability Not applicable Materials availability Not applicable Code availability Not applicable Author contribution H.-J.L.; methodology, project administration, supervision, writing—original draft preparation; H.H. and J.-E.K.; validation, investigation, data curation, and software. All the authors have read and agreed to the published version of the manuscript. References abcam. Available from: https://www.abcam.com/products?sortOptions=Relevance&keywords=picrosirius+red . World Health Organization. Coronavirus disease (COVID-19). 2023; Available from: https://www.who.int/health-topics/coronavirus#tab=tab_1 . Ye Q, Wang B, Mao J. Cytokine storm in COVID-19 and treatment. J Infect. 2020;80(6):607–13. Grasselli G, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome–Authors' reply. Lancet Respiratory Med. 2021;9(1):e5–6. Fara A, et al. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open biology. 2020;10(9):200160. Ukwenya VO, et al. The Impact of Deranged Glucose Metabolism and Diabetes in the Pathogenesis and Prognosis of the Novel SARS-CoV-2: A Systematic Review of Literature. Curr Diabetes Rev. 2022;18(3):101–12. Taniguchi-Ponciano K, et al. Increased expression of hypoxia-induced factor 1α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients. Ann Med. 2021;53(1):197–207. Tian M, et al. HIF-1α promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19. Signal Transduct Target Therapy. 2021;6(1):308. Allen SP, et al. Transcriptomic analysis of human astrocytes in vitro reveals hypoxia-induced mitochondrial dysfunction, modulation of metabolism, and dysregulation of the immune response. Int J Mol Sci. 2020;21(21):8028. Ménégaut L et al. Interplay between liver X receptor and hypoxia inducible factor 1α potentiates interleukin-1β production in human macrophages. Cell Rep, 2020. 31(7). Liu J, et al. CCR7 chemokine receptor-inducible lnc-Dpf3 restrains dendritic cell migration by inhibiting HIF-1α-mediated glycolysis. Immunity. 2019;50(3):600–15. e15. Jahani M, Dokaneheifard S, Mansouri K. Hypoxia: A key feature of COVID-19 launching activation of HIF-1 and cytokine storm. J Inflamm. 2020;17(1):1–10. Codo AC, et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis. Cell Metabol. 2020;32(3):437–46. e5. Pearce L, Davidson SM, Yellon DM. The cytokine storm of COVID-19: a spotlight on prevention and protection. Expert Opin Ther Targets. 2020;24(8):723–30. Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020;50(9):611–9. Lim H-S, et al. Apigetrin from Scutellaria baicalensis Georgi inhibits neuroinflammation in BV-2 microglia and exerts neuroprotective effect in HT22 hippocampal cells. J Med Food. 2016;19(11):1032–40. Hadrich F, Sayadi S. Apigetrin inhibits adipogenesis in 3T3-L1 cells by downregulating PPARγ and CEBP-α. Lipids Health Dis. 2018;17:1–8. Kim SM, et al. Apigetrin induces extrinsic apoptosis, autophagy and G2/M phase cell cycle arrest through PI3K/AKT/mTOR pathway in AGS human gastric cancer cell. J Nutr Biochem. 2020;83:108427. Guo H, Li M, Xu L-J. Apigetrin treatment attenuates LPS-induced acute otitis media though suppressing inflammation and oxidative stress. Biomed Pharmacother. 2019;109:1978–87. Sun Q, Lu N-N, Feng L. Apigetrin inhibits gastric cancer progression through inducing apoptosis and regulating ROS-modulated STAT3/JAK2 pathway. Biochem Biophys Res Commun. 2018;498(1):164–70. Lee Y-K, et al. AKT, a Key Transmitter of HIF-1α and AR Signaling Pathways, Has a Critical Role in the Apigetrin-Mediated Anti-Cancer Effects in Prostate Cancer Cells. Biomedicines. 2022;10(6):1370. Amin BJH, et al. Post COVID-19 pulmonary fibrosis; a meta-analysis study. Annals Med Surg. 2022;77:103590. Zheng Z, Peng F, Zhou Y. Pulmonary fibrosis: A short-or long-term sequelae of severe COVID-19? Chinese Medical Journal-Pulmonary and Critical Care Medicine, 2023. Mylvaganam RJ et al. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. Eur respiratory Rev, 2021. 30(162). Kramer D, Hilton R, Roman J. Pulmonary fibrosis and COVID-19. The American Journal of the Medical Sciences; 2023. Florescu S, et al. Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19: a randomized clinical trial. JAMA. 2023;329(14):1183–96. Zhang R, et al. Role of HIF-1α in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. Am J Physiology-Lung Cell Mol Physiol. 2009;297(4):L631–40. Pang J, et al. Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment. Obes Med. 2021;22:100312. Kuba K, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med. 2005;11(8):875–9. Imai Y, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–6. Li W, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4. Tai W, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17(6):613–20. El-Saber Batiha G, et al. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology. 2022;30(4):1189–205. Yang R, Yu Y. Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers. Int J Biol Sci. 2021;17(6):1530. Ciechanowicz P, et al. JAK-inhibitors in dermatology: current evidence and future applications. J Dermatological Treat. 2019;30(7):648–58. Jamilloux Y, et al. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun rev. 2019;18(11):102390. Costela-Ruiz VJ, et al. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62–75. Sun X, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38–42. McElvaney OJ, et al. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med. 2020;202(6):812–21. Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–15. Tzouvelekis A, et al. Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1α in disease pathogenesis. Am J Respir Crit Care Med. 2007;176(11):1108–19. Higgins DF, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Investig. 2007;117(12):3810–20. Manresa MC, Godson C, Taylor CT. Hypoxia-sensitive pathways in inflammation-driven fibrosis. Am J Physiology-Regulatory Integr Comp Physiol. 2014;307(12):R1369–80. Chen J-Y, et al. Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis. Chin Med J. 2020;133(12):1390–6. Das A, Patra M, Dhangadamajhi G. Association of rs11549465 (C1772T) variant of hypoxia-inducible factor-1α with Covid-19 susceptibility. A population-based epidemiological study. Hum Cell. 2021;34(6):1937–40. Wing PA et al. Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells. Cell Rep, 2021. 35(3). Gani M, et al. Possible silent hypoxemia in a COVID-19 patient: a case report. Annals Med Surg. 2020;60:583–6. Rysz S, et al. COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system. Nat Commun. 2021;12(1):2417. Devaux CA, Raoult D. The impact of COVID-19 on populations living at high altitude: Role of hypoxia-inducible factors (HIFs) signaling pathway in SARS-CoV-2 infection and replication. Front Physiol. 2022;13:960308. Krick S, et al. Hypoxia-driven proliferation of human pulmonary artery fibroblasts: cross‐talk between HIF‐1α and an autocrine angiotensin system. FASEB J. 2005;19(7):1–26. Ha S-E, et al. Apigetrin Abrogates Lipopolysaccharide-Induced Inflammation in L6 Skeletal Muscle Cells through NF-κB/MAPK Signaling Pathways. Curr Issues Mol Biol. 2022;44(6):2635–45. Luo G, Zhu W. Apigetrin inhibits cytotoxicity and dysregulation of ACE2, IL1α and TGFβ expression induced by recombinant spike protein of SARS-CoV-2. World J Adv Res Reviews. 2021;9(2):144–54. Manokaran S et al. Molecular docking and pharmacokinetic studies of naturally occurring flavonoid glycosides and their activity against COVID-19 viral proteins. SPAST Abstracts, 2021. 1(01). Additional Declarations No competing interests reported. Supplementary Files SupplementaryMaterial1westernblotting.pptx Supplementary Material 1: Supplementary original blot images. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4131121","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":281843636,"identity":"41a36290-2311-4f75-acaf-1dc5a4273d99","order_by":0,"name":"Hengmin Han","email":"","orcid":"","institution":"Kyung Hee University","correspondingAuthor":false,"prefix":"","firstName":"Hengmin","middleName":"","lastName":"Han","suffix":""},{"id":281843637,"identity":"e3e3f09a-0ec4-46e7-b5e8-378aaebe9d01","order_by":1,"name":"Jung-Eun Kim","email":"","orcid":"","institution":"Kyung Hee University","correspondingAuthor":false,"prefix":"","firstName":"Jung-Eun","middleName":"","lastName":"Kim","suffix":""},{"id":281843639,"identity":"55e393f4-0027-4882-8d4b-603094df9785","order_by":2,"name":"Hyo-Jeong Lee","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA1klEQVRIiWNgGAWjYPCC/3L8PDwQpgRBxWxgktlYsodULYkbzhCrRX5+78PHBb/YEjefOXtMgqHGjkFy9gH8WgyOsRsbz+zjMd52ti9NguFYMoM0XwIBLWxsbNK8PRKy287zmEkwsB1gkOMh5LA2sBYDxs39IC3/iNDCcAyohedHguIG3h4zCca2AwzShLQYHEtjNuZtOGAsceaMsUViXzKPZA8hhzUfY3zM8+eAHH9PjuGND9/s5CTOEHIYCDC2QRkJDAwEfQIFf4hUNwpGwSgYBSMTAABvCjbAhvIObwAAAABJRU5ErkJggg==","orcid":"","institution":"Kyung Hee University","correspondingAuthor":true,"prefix":"","firstName":"Hyo-Jeong","middleName":"","lastName":"Lee","suffix":""}],"badges":[],"createdAt":"2024-03-19 14:29:44","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4131121/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4131121/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":53417539,"identity":"f1fbd160-7554-4597-a4ff-26e75e38956c","added_by":"auto","created_at":"2024-03-25 18:04:30","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":54138,"visible":true,"origin":"","legend":"\u003cp\u003eEvaluation of \u003cem\u003ein vitro\u003c/em\u003e ARDS and PF model. MH-S (A) and THP-1 cells (B) were infected with PSCV for 24 h. Cell lysates were prepared and subjected to western blotting to analyze the expression of Spike1, HIF-1α, IL-6, IL-1β, TNF-α, and β-actin. MRC-5 cells were treated with CMPSCV from MH-S (C) or THP-1 (D) cells for 24 h. Cell lysates were prepared and subjected to western blotting to analyze the CTGF, COLA1, α-SMA, HIF-1α, and β-actin expressions. The results are presented as the mean ± SD of three independent experiments. ** \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.01, and *** \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.001 (compared to normal control)\u003c/p\u003e","description":"","filename":"Fig1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4131121/v1/dff729c122519c1a7483cfc8.jpg"},{"id":53417544,"identity":"331832f9-ef55-40b0-86b8-9dec8a40501c","added_by":"auto","created_at":"2024-03-25 18:04:31","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":64640,"visible":true,"origin":"","legend":"\u003cp\u003eEffect of HIF-1α siRNA and CoCl\u003csub\u003e2\u003c/sub\u003e in PSCV-infected MH-S or THP-1 cells and CPMSCV-exposure MRC-5 cells. MH-S (A) and THP-1 cells (B) were transfected with HIF-1α siRNA for 48 h and were incubated in the presence or absence of PSCV for 24 h. PSCV-infected MH-S (C) and THP-1 cells (D) were treated with CoCl\u003csub\u003e2\u003c/sub\u003e for 24 h. Cell lysates were prepared and subjected to western blotting to analyze the Spike1, HIF-1α, IL-6, IL-1β, TNF-α, and β-actin expressions. The results are presented as the mean ± SD of three independent experiments.\u0026nbsp;\u003csup\u003e\u003cem\u003e## \u003c/em\u003e\u003c/sup\u003e\u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.01,\u0026nbsp;\u003csup\u003e### \u003c/sup\u003e\u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.001 (compared to normal control), ** \u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.01, and *** \u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.001 (compared to PSCV-infected control). MRC-5 cells were transfected with HIF-1α siRNA for 48 h and were incubated in the presence or absence of PSCV-treated MH-S (E) or THP-1 cells (F) CMPSCV for 24 h. Cell lysates were prepared and subjected to western blotting to analyze the CTGF,\u003cstrong\u003e \u003c/strong\u003eCOLA1, α-SMA, HIF-1α, and β-actin expressions. The results are presented as the mean ± SD of three independent experiments.\u0026nbsp;\u003csup\u003e##\u003c/sup\u003e\u0026nbsp;\u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.01,\u0026nbsp;\u003csup\u003e###\u003c/sup\u003e\u0026nbsp;\u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.001 (compared to normal control), ** \u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.01, and *** \u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.001 (compared to CMPSCV-infected control)\u003c/p\u003e","description":"","filename":"Fig2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4131121/v1/3d406657e86a5c8fc67707ac.jpg"},{"id":53417541,"identity":"b148d632-13a8-46e9-82a8-66a83957009c","added_by":"auto","created_at":"2024-03-25 18:04:30","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":53156,"visible":true,"origin":"","legend":"\u003cp\u003eEvaluation of apigetrin on spike protein expression and binding to S protein RBD in PSCV-infected MH-S and THP-1 cells. (A) The SARS-CoV-2 inhibitor screening kit was used to test the ability of apigetrin to bind to SARS-CoV-2 S protein RBD. The results are presented as the mean ± SD of three independent experiments. *** \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.001 (compared to normal control). MH-S (B) and THP-1 cells (C) were treated with PSCV and apigetrin for 24 h. The cells were fixed in 100% methanol, exposed to the diluted Spike 1 antibody, and incubated with the goat anti-rabbit IgG. The reacted cells were incubated with VECTASHIELD® antifade mounting medium with DAPI, and the image was captured using a fluorescence microscope. a~c means in a row by different superscripts aresignificantly different by LSD (least significant difference).\u003c/p\u003e","description":"","filename":"Fig3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4131121/v1/71b09cc8702e595eba688160.jpg"},{"id":53417543,"identity":"fe56bb3d-bd60-451e-8d29-8fb1f2b74fe3","added_by":"auto","created_at":"2024-03-25 18:04:31","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":47387,"visible":true,"origin":"","legend":"\u003cp\u003eAnti-inflammatory effect of apigetrin in PSCV-infected MH-S and THP-1 cells. MH-S (\u003cstrong\u003eA\u003c/strong\u003e) and THP-1 cells (B) were infected with PSCV and apigetrin for 24 h. Cell lysates were prepared and subjected to western blotting to analyze the Spike1, HIF-1α, IL-6, IL-1β, TNF-α, and β-actin expressions. IL-6, IL-1β, and TNF-α concentrations in the serum samples of MH-S (C-E), and THP-1 (F-H) cells were determined by ELISA. The results are presented as the mean ± SD of three independent experiments.\u0026nbsp;\u003csup\u003e##\u003c/sup\u003e\u0026nbsp;\u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.01,\u0026nbsp;\u003csup\u003e###\u003c/sup\u003e\u0026nbsp;\u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.001 (compared to normal control), **\u0026nbsp;\u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.01, and ***\u0026nbsp;\u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.001 (compared to PSCV-infected control)\u003c/p\u003e","description":"","filename":"Fig4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4131121/v1/5208778914f09d394753e231.jpg"},{"id":53417542,"identity":"11510a84-c584-4ba2-a0ec-57518702e9f0","added_by":"auto","created_at":"2024-03-25 18:04:30","extension":"jpg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":55058,"visible":true,"origin":"","legend":"\u003cp\u003eEffect of apigetrin on pulmonary fibrosis in CMPSCV-treated MRC-5 cell model. MRC-5 cells were treated with apigetrin in MH-S (A, B) or THP-1 cells (D, E) CMPSCV for 24 h. CELLOMAX\u003csup\u003eTM\u003c/sup\u003e kit was used to measure cell proliferation. a~c means in a row by different superscripts are significantly different by LSD (least significant difference). After treatment the cells were resolved in 3.5% formaldehyde, permeabilized by methanol, and stained by crystal violet. Picro-Sirius Red Stain Kit was used to stain collagen fibers and the image was captured using a light microscope (B, E). a~d means in a row by different superscripts are significantly different by LSD (least significant difference). MRC-5 cells were treated with apigetrin in MH-S (C) or THP-1 cells (F) CMPSCV for 24 h. Cell lysates were prepared and subjected to western blotting to analyze the CTGF, COLA1, α-SMA, HIF-1α, and β-actin expressions. The results are presented as the mean ± SD of three independent experiments at\u0026nbsp;\u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.05.\u0026nbsp;\u003csup\u003e##\u003c/sup\u003e\u0026nbsp;\u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.01,\u0026nbsp;\u003csup\u003e###\u003c/sup\u003e\u0026nbsp;\u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.001 (compared to normal control), **\u0026nbsp;\u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.01, and ***\u0026nbsp;\u003cem\u003ep\u003c/em\u003e\u0026nbsp;\u0026lt; 0.001 (compared to CMPSCV-infected control)\u003c/p\u003e","description":"","filename":"Fig5.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4131121/v1/dedcc4103f64e6d5370c2f48.jpg"},{"id":54104322,"identity":"8521107e-377d-49cb-9a23-eab6fd8cf420","added_by":"auto","created_at":"2024-04-04 16:38:28","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":600579,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4131121/v1/84e2338f-8c84-42e6-80f7-44c7fa17afc6.pdf"},{"id":53417568,"identity":"209fa0c7-add7-417f-b513-57b20de1a5ad","added_by":"auto","created_at":"2024-03-25 18:04:36","extension":"pptx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":61713124,"visible":true,"origin":"","legend":"\u003cp\u003eSupplementary Material 1: Supplementary original blot images.\u003c/p\u003e","description":"","filename":"SupplementaryMaterial1westernblotting.pptx","url":"https://assets-eu.researchsquare.com/files/rs-4131121/v1/6cc34da66443d49a0b7bb927.pptx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Effect of apigetrin in pseudo-SARS-CoV-2-induced inflammatory and pulmonary fibrosis in vitro model","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eCovid-19 is an infectious coronavirus disease caused by SARS-CoV-2 virus. Most SARS-CoV-2-infected individuals experience mild-to-moderate illness and recover without special treatment [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. However, patients with advanced age, cardiovascular disease, diabetes, obesity, chronic respiratory disease, and cancer are more likely to develop severe illnesses and require medical attention. Recently, a variant mutation type of SARS-CoV-2 has emerged. SARS-CoV-2 and its variants cause short- or long-term lung complications such as pneumonia, acute respiratory distress syndrome (ARDS), sepsis, and bronchitis. Furthermore, SARS-CoV-2 leaves sequelae. The post-acute sequelae of COVID-19 (PASC) include interstitial lung disease (ILD) and pulmonary fibrosis (PF). Post-COVID-19 ILD and PF respiratory symptoms include a chronic dry cough, fatigue, and dyspnea. Ap-proximately 44.9% of COVID-19 survivors appeared to have developed PF. Factors related to COVID-19 severity were significantly associated with post-COVID-19 PF (PCPF) development.\u003c/p\u003e \u003cp\u003eCOVID-19 has the potential to elicit a cytokine storm in pulmonary tissues, marked by immune system overactivation and unregulated cytokine release [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e] Cytokine storms can lead to a severe clinical complication called ARDS. ARDS is triggered by an exaggerated immune response rather than viral load [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. Studies have found that extraordinarily high proinflammatory cytokine levels in SARS cytokine release syndrome, such as TNF-α, IL-6, IL-8, IL-1β, IL-12, IL-17, IFN-γ, IP10, and MCP1, are the probable causes and clinical outcomes of this phenomenon in severe COVID-19 cases and contribute to COVID-19 pathogenesis and related complications, including pulmonary inflammation and extensive lung damage [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Several studies showed that the upregulation and participation of hypoxia-inducible factor-1α (HIF-1α) relate to inflammation, immunometabolism, and TLR in bronchoalveolar cells of critically severe COVID-19 patients [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Also, high HIF-1α levels were detected in peripheral blood monocytes of COVID-19 patients and infected cells [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. The HIF-1α acts as a key regulator in physiological functions including metabolism, cell proliferation, and angiogenesis [\u003cspan additionalcitationids=\"CR10\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. HIF-1α is also an important activator in glycolysis and inflammatory response, which implies the effects of HIF-1α on the pathogenesis of COVID-19 [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eRecently, many studies have reported the development of SARS-CoV-2 vaccines and drugs. However, most targeted therapeutics against SARS-CoV-2 focus on vaccines or blockers of entry into cells to prevent SARS-CoV-2 infection. Supportive therapeutic interventions and antiviral agents with limited efficacy are required to reduce the COVID-19 outbreak and mitigate its symptoms [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Although much research has focused on developing vaccines and antiviral therapies to prevent or treat SARS-CoV-2 infection, studying their long-term effects and post-infection complications is crucial. Few studies have targeted inflammation (immunomodulatory properties). Few studies have investigated targeted therapeutic agents for post-SARS-CoV-2-related lung diseases. Furthermore, most SARS-CoV-2 experiments are difficult to perform in a laboratory without biosafety level 3 (BSL-3) permission. Therefore, a reliable, rapid, and convenient \u003cem\u003ein vitro\u003c/em\u003e model of SARS-CoV-2-related lung disease that can be handled in a BSL-2 laboratory is essential for screening and evaluating therapeutic agents against SARS-CoV-2 infection. Therefore, based on SARS-CoV-2 clinical data reported, we established \u003cem\u003ein vitro\u003c/em\u003e models of ARDS and PF using pseudotyped SARS-CoV-2 virus, and inflammation and PF-related markers were assessed in this study.\u003c/p\u003e \u003cp\u003eNatural products have received considerable attention as potential therapeutic options. Flavonoids, naturally occurring polyphenolic compounds in fruits and vegetables, have received significant attention owing to their anticancer, anti-inflammatory, antioxidant, antibacterial, fungal, and viral properties. Therefore, flavonoid-rich flavonoids and plants are considered applicable agents for treating COVID-19, and their potentially beneficial role is currently a widely discussed topic. Apigetrin, apigenin 7-O-glucoside, and cosmosin are flavonoid glycosides commonly found in natural sources. Apigenin has various beneficial properties including antioxidant, anti-obesity, anticancer, and anti-inflammatory effects [\u003cspan additionalcitationids=\"CR17 CR18 CR19\" citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. We have determined that apigetrin has an anti-cancer effect by inhibiting HIF-1α [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. Therefore, based on the reported data on apigetrin, we evaluated the effect of apigetrin on SARS-CoV-2 complications mimicking \u003cem\u003ein vitro\u003c/em\u003e models.\u003c/p\u003e"},{"header":"2. Materials and Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1. Test Chemical\u003c/h2\u003e \u003cp\u003eApigetrin (M.W\u0026thinsp;=\u0026thinsp;432.38 g/mol, purity\u0026thinsp;\u0026ge;\u0026thinsp;97% as determined through HPLC) was purchased from Sigma-Aldrich (Cat: 44692, St. Louis, MO, USA). HIF-1α siRNA was purchased from Santa Cruz (Cat: sc-35561, Dallas, TX, USA), and CoCl\u003csub\u003e2\u003c/sub\u003e was purchased from Sigma-Aldrich (Cat: C8661, St. Louis, MO, USA).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2. Cell Culture\u003c/h2\u003e \u003cp\u003eMH-S (Cat: CRL-2019, American Type Culture Collection (ATCC), Manassas, VA, USA) and THP-1 cells (Cat: TIB-202, ATCC, Manassas, VA, USA) were cultured in RPMI 1640 (Cat: LM 011\u0026thinsp;\u0026minus;\u0026thinsp;01, WELGENE, Daegu, Korea) medium supplemented with 10% fetal bovine serum (Cat: S101-07, WELGENE, Daegu, Korea) and 1% antibiotics (Cat: LS203-01, WELGENE, Daegu, Korea). Lenti-XTM 293T (Cat: 632180, Takara Bio Inc., Shiga, Japan) and MRC-5 (Cat: 10171, KCLB, Seoul, Korea) cells were cultured in DMEM (Cat: LM-001-05, WELGENE, Daegu, Korea) medium supplemented with 10% FBS and 1% antibiotics. All the cells were cultured in a humidified atmosphere at 37\u0026deg;C containing 5% CO\u003csub\u003e2\u003c/sub\u003e to maintain the required physiological conditions.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e2.3. SARS-CoV-2 Pseudo-Typed Lentivirus\u003c/h2\u003e \u003cp\u003eLenti-X 293T cells (5 \u0026times; 10\u003csup\u003e6\u003c/sup\u003e) were seeded/10 cm plate in complete medium for 24 h. The Lenti-X\u0026trade; SARS-CoV-2 Packaging Single Shots (Takara, Vancouver, Canada) were used to cultivate the SARS-CoV-2 pseudotyped lentivirus. After 4 h treating Lenti-X\u0026trade; SARS-CoV-2 Packaging Single Shots, 6 mL of fresh complete growth medium was added and incubated at 37\u0026deg;C, 5% CO\u003csub\u003e2\u003c/sub\u003e for an additional 48 h. 5X107 pseudo-SARS-CoV-2 were used to infect MH-S and THP-1 cells.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e2.4. Immunofluorescence\u003c/h2\u003e \u003cp\u003eMH-S and THP-1 cells (1 \u0026times; 10\u003csup\u003e4\u003c/sup\u003e cells) were seeded in confocal dishes (Cat: 210350; SPL, Pocheon, Korea). After, the cells were incubated for 24 h at 37\u0026deg;C containing 5% CO\u003csub\u003e2\u003c/sub\u003e, treated with PSCV and apigetrin (10 \u0026micro;M) for 24 h, then were fixed in 100% methanol (chilled at -20\u0026deg;C) at room temperature for 5 min. The fixed cells were exposed to the di-luted Spike 1 (Cat: 99423, Cell Signaling, Danvers, MA, USA) antibody in 1% BSA in PBST in a humidified chamber overnight at 4\u0026deg;C. Then, cells were incubated with the goat anti-rabbit IgG (Alexa Fluor\u0026reg; 488) (Cat: ab150077, Abcam, Cambridge, UK) in 1% BSA for 1 h at room temperature in the dark. The reacted cells were incubated with VECTASHIELD\u0026reg; antifade mounting medium with DAPI (Cat: H-1200-10, Vector Laboratories, Burlingame, CA, USA) for 3 min. Images were captured randomly and each slide was imaged using a fluorescence microscope (Nikon, Tokyo, Japan).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e2.5. SARS-CoV-2 Binding Assay\u003c/h2\u003e \u003cp\u003eA SARS-CoV-2 inhibitor screening kit (Cat: EP-105, ACROBIOSYSTEMS, Newark, DE 19711, USA) was used to test the ability of apigetrin to bind to the SARS-CoV-2 S protein RBD. SARS-CoV-2 S protein RBD stock solution (100 \u0026micro;g/mL) was diluted to 0.5 \u0026micro;g/mL with a coating buffer to make the SARS-CoV-2 S protein RBD working solution. Biotinylated human ACE2 stock solution (100 \u0026micro;g/mL) was diluted to 0.12 \u0026micro;g/mL with a dilution buffer to make a biotinylated human ACE2 working solution. A total of 50 uL of apigetrin (10 \u0026micro;M) was added, and the plate was sealed with a microplate sealing film and incubated for 1 h. Streptavidin-HRP stock solution (50 \u0026micro;g/mL) was diluted to 0.1 \u0026micro;g/mL with a dilution buffer and incubated for 1 h. Then, 100 \u0026micro;L of Streptavidin-HRP working solution was added and incubated for 1 h. TMB Substrate Working Solution (200 \u0026micro;L) was added to each well and incubated for 20 min. Then, 50 \u0026micro;L of stop solution was added and tapped gently for 3 min. The absorbance was measured at 450 nm using a UV microplate spectrophotometer.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e2.6. Western Blot Analysis\u003c/h2\u003e \u003cp\u003eProtein samples were obtained by lysing cells in radioimmunoprecipitation assay (RIPA) buffer, which comprised 50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 M EDTA, 1 mM Na\u003csub\u003e3\u003c/sub\u003eVO\u003csub\u003e4\u003c/sub\u003e, 1 mM NaF, and protease inhibitor cocktail (Cat: 89900, 87786, 78420, Thermo, Waltham, MA, USA). Protein concentration was determined using the Bio-Rad DC Protein Assay Kit II (Cat: 500\u0026thinsp;\u0026minus;\u0026thinsp;0113, 500\u0026thinsp;\u0026minus;\u0026thinsp;0114, 500\u0026thinsp;\u0026minus;\u0026thinsp;0115, Bio-Rad, Hercules, CA, USA). The quantified protein samples were loaded onto 8\u0026ndash;15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred onto a Hybond transfer membrane (Cat: 10600002, 10600001, Amersham Pharmacia, Piscataway, NJ, USA) using a transfer system at 250 mA for 2 h. Non-specific binding on membranes was blocked in fresh 5% non-fat dry milk (Cat: DI-232100, BD, Franklin Lakes, NJ, USA), after which the membranes were incubated with primary antibodies against IL-6 (ratio 1:2000, Cat: SC-28343, Santa Cruz, Dallas, TX, USA), Spike1 (ratio 1:1000, Cat: 99423, Cell Signaling, Danvers, MA, USA), IL-1β (ratio 1:1000, Cat: SC-12742, Santa Cruz, Dallas, TX, USA), TNF-α (ratio 1:1000, Cat: SC-52746, Santa Cruz, Dallas, TX, USA), CTGF (ratio 1:1000, Cat: SC-101586, Santa Cruz, Dallas, TX, USA), COLA1 (ratio 1:1000, Cat: ab6308, Abcam, Cambridge, UK), α-SMA (ratio 1:1000, Cat: SC-53015, Santa Cruz, Dallas, TX, USA), HIF-1α (ratio 1:500, Cat: NB100-105, NOVUS, Littleton, CO, USA), and β-actin (ratio 1:10000, Cat: A5316, Sigma-Aldrich, St. Louis, MO, USA) overnight at 4\u0026deg;C. Mem-branes were incubated with horseradish peroxidase (HRP)-conjugated anti-mouse (ratio 1:10000, Cat: 115-035-003; Jackson, West Grove, PA, USA) or anti-rabbit secondary anti-bodies (ratio 1:10000, Cat: 111-035-003, Jackson, West Grove, PA, USA). An enhanced chemiluminescence (ECL) system (Cat: RPN2209; Amersham Pharmacia, Piscataway, NJ, USA) was used for the protein expression analysis. Densitometric data were obtained by quantifying each protein band using ImageJ 1.53k (National Institutes of Health, Bethesda, MD, USA). Protein levels were quantified from the duplicate analyses of each sample. Protein levels of interest were normalized to β-actin.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003e2.7. SARS-CoV-2 Cytokines Secretion Quantification\u003c/h2\u003e \u003cp\u003eMH-S and THP-1 cells (1 \u0026times; 10\u003csup\u003e6\u003c/sup\u003e) were seeded in a 60 mm cell culture dish and incubated for 24 h. The cells were treated with or without PSCV and apigetrin (10 \u0026micro;M) for 24 h, then the supernatant was harvested. The secretion of TNF-α, IL-6, and IL-1β by MH-S or THP-1 cells was measured using ELISA with a paired set of antibodies and HRP-labeled streptavidin (Cloud-Clone, Cat: SEA079Hu, SEA133Hu, SEA563Hu, SEA563Mu, SEA133Mu, SEA079Mu, Katy, TX, USA). The optical density was measured at 450 nm using a microplate reader (Sunrise RC, Tecan, Mannedorf, Switzerland).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003e2.8. Cell Proliferation Assay\u003c/h2\u003e \u003cp\u003eMRC-5 cells (1 \u0026times; 10\u003csup\u003e4\u003c/sup\u003e) were seeded in 96-well plates (Cat: 30096; SPL, Pocheon, Korea) and incubated for 24 h. The cells were treated with or without apigetrin (10 \u0026micro;M) in CMP-SCV for 24 h. Cell viability was evaluated using a CELLOMAXTM viability kit (Cat: CM-VA2500, Precaregene, Hanam, Korea). CELLOMAXTM reagent (10 \u0026micro;L) was added to each well and was incubated in the dark. The optical density was measured at 450 nm using a microplate reader (Sunrise RC, Tecan, Mannedorf, Switzerland).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003e2.9. Migration Assay\u003c/h2\u003e \u003cp\u003eMRC-5 cells (5 \u0026times; 10\u003csup\u003e4\u003c/sup\u003e) were seeded into a Cell Culture Insert (Cat: 36224, SPL, Pocheon, Korea) at a density of 2.5 \u0026times; 10\u003csup\u003e5\u003c/sup\u003e/mL in a serum-free medium. 700 \u0026micro;L of CMPSCV or CTP-SCV medium (with serum) treated with or without apigetrin in the lower chamber. Trans-fer the insert into the lower chamber. The plates were incubated for 24 h at 37\u0026deg;C containing 5% CO\u003csub\u003e2\u003c/sub\u003e. The medium was removed, and the cells were washed with PBS. Cells were fixed with 3.5% formaldehyde (in PBS) at room temperature for 2 min and permeabilized with methanol at room temperature for 20 min. The cells were then stained with crystal violet at room temperature for 15 min. Nonmigratory cells were scraped off using cotton swabs. Images were captured under a light microscope (Nikon, Tokyo, Japan).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003e2.10. Statistical Analysis\u003c/h2\u003e \u003cp\u003eThe data presented in this study are expressed as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation (S.D.) and were obtained from three replicates for each experiment. Analysis of variance was used to assess the significance of differences between groups. A p-value less than 0.05 was considered statistically p\u0026thinsp;\u0026lt;\u0026thinsp;0.05. Significance was evaluated using the Sigma Plot software. (\u003csup\u003e*\u003c/sup\u003e p\u0026thinsp;\u0026lt;\u0026thinsp;0.05, \u003csup\u003e**\u003c/sup\u003e p\u0026thinsp;\u0026lt;\u0026thinsp;0.01, \u003csup\u003e***\u003c/sup\u003e p\u0026thinsp;\u0026lt;\u0026thinsp;0.001). Data were analyzed by one-way ANOVA, followed by Tukey\u0026rsquo;s studentized range test using the GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA). Means with different letters are significantly different between the groups.\u003c/p\u003e \u003c/div\u003e"},{"header":"3. Results","content":"\u003cp\u003e3.1. \u003cem\u003eIn vitro\u0026nbsp;\u003c/em\u003eARDS model using PSCV in MH-S and THP-1 cells shows increased proinflammatory cytokines and HIF-1\u0026alpha;\u003c/p\u003e\n\u003cp\u003eLipopolysaccharide-treated MH-S cells were used as an \u003cem\u003ein vitro\u003c/em\u003e model of ARDS. We modified this model to establish an \u003cem\u003ein vitro\u003c/em\u003e model that mimics ARDS caused by SARS-CoV-2. An \u003cem\u003ein vitro\u003c/em\u003e model, a SARS-CoV-2 ARDS mimic, was produced by treating THP-1 and MH-S cells with PSCV instead of LPS. We checked the proinflammatory cytokines and HIF-1\u0026alpha; levels that have been reported as highly expressed in SARS-CoV-2 patients. Spike protein-1 was used to confirm the infection of cells with PSCV. As shown in Figures 1A and B, IL-6, IL-1\u0026beta;, TNF-\u0026alpha;, and HIF-1\u0026alpha; showed over 1.5-fold higher expression than PSCV-non-treated cells in MH-S and THP-1 cells. Especially, HIF-1\u0026alpha; expression indicated 2.8- and 9.2-fold higher expression than PSCV-non-treated cells in, respectively, MH-S and THP-1 cells.\u003c/p\u003e\n\u003cp\u003e3.2. \u003cem\u003eIn vitro\u0026nbsp;\u003c/em\u003ePF model using a conditioned medium of PSCV-treated MH-S or THP-1 cells (CMPSV) in MRC-5 cells shows increased expression of CTGF, COLA1, \u0026alpha;-SMA, and HIF-1\u0026alpha;\u003c/p\u003e\n\u003cp\u003ePF is frequently reported as a COVID-19 sequela of [22-25]. As elevated cytokine levels regulate the initiation and progression of fibrosis and remodeling, an\u003cem\u003e\u0026nbsp;in vitro\u003c/em\u003e model mimicking SARS-CoV-2 PF was produced by treating MRC-5 cells with CMPSCV. CMPSCV is a culture medium obtained after a 48-hour culture of culturing PSCV-infected MH-S or THP-1 cells. The \u003cem\u003ein vitro\u0026nbsp;\u003c/em\u003ePF model was established by culturing MRC-5 cells in the two types of CMPSCV for 24 h. If CMPSV is involved in MRC-5 differentiation to change fibroblast to myofibroblast, we expected MRC-5 cells to increase CTGF, COLA-1, and \u0026alpha;-SMA. As shown in Figure 1C and D, CTGF, COLA1, \u0026alpha;-SMA, and HIF-1\u0026alpha; expression significantly increased in CMPSV of MHS or THP-1 cells compared to the control group, without CMPSV.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e3.3. HIF-1\u0026alpha; knockdown ameliorates inflammation induced by PSCV infection in MH-S and THP-1 cells and decreases increased CTGF, COLA1, and \u0026alpha;-SMA in CPMSCV-exposure MRC-5 cells\u003c/p\u003e\n\u003cp\u003eTo confirm the role of HIF-1\u0026alpha; in the PSCV-induced inflammation in MH-S and THP-1 cells, HIF-1\u0026alpha; knockdown experiments were performed. HIF-1\u0026alpha; protein 6.9 and 6.64 folds higher expressed in PSCV-infected MH-S and THP-1 cells compared with non-infected MH-S and THP-1 cells, while HIF-1\u0026alpha; siRNA blocked the PSCV-induced HIF-1\u0026alpha; protein expression in MH-S and THP-1 cells. Also, HIF-1\u0026alpha; siRNA suppressed inflammatory proteins IL-6, IL-1\u0026beta;, and TNF-\u0026alpha; levels increased in PSCV-infected MH-S and THP-1 cells (Figure 2A and B). Spike protein was confirmed as a PSCV infection marker. Spike protein showed strong expression in PSCV-infected MH-S cells and THP-1 cells, while the spike protein was decreased by treating HIF-1\u0026alpha; siRNA to PSCV-infected MH-S and THP-1 cells (Figure 2A and B). In contrast, cobalt chloride (CoCl\u003csub\u003e2\u003c/sub\u003e), a hypoxia mimic and inhibitor of HIF-1\u0026alpha; degradation, induced inflammatory cytokines in the PSCV-exposure THP-1 cells. In PSCV-treated MH-S cells, CoCl\u003csub\u003e2\u003c/sub\u003e maintained the levels of cytokines that were increased by PSCV (Figure 2C and D). HIF-1\u0026alpha; siRNA decreased increased CTGF, COLA1, \u0026alpha;-SMA, and HIF-1\u0026alpha; in CPMSCV-cultured MRC-5 cells (Figure 2E and F).\u003c/p\u003e\n\u003cp\u003e3.4. Apigetrin obstructs entering SARS-CoV-2 into the cells.\u003c/p\u003e\n\u003cp\u003eThe initial attachment of SARS-CoV-2 to cells involves specific binding between the viral spike (S) glycoprotein and the cellular receptor ACE2. To evaluate whether apigetrin interferes with the formation of the S-ACE2 complex, a SARS-CoV-2 S-ACE2 binding ELISA kit was used. Apigetrin displayed 34% blocking activity between the binding spike S RBD: ACE2 receptor (Figure. 3A). Additionally, we checked the spike protein in the cells after infection with PSCV to MH-S and THP-1 cells. As shown in Figure 1B and C, the spike protein was highly expressed in PSCV-infected MH-S and THP-1 cells. Spike protein expression decreased in PSCV-infected MH-S and THP-1 cells treated with apigetrin. The spike protein expression of apigetrin was reduced by 3.3 and 2.8 folds, respectively, compared with the PSCV-treated MH-S and THP-1 cells (Figure 3A).\u003c/p\u003e\n\u003cp\u003e3.5. Apigetrin inhibited the inflammatory effect induced by PSCV infection in MHS and THP-1 cells.\u003c/p\u003e\n\u003cp\u003ePSCV-infected MH-S or THP-1 cells showed an increase over two-fold in inflammatory relative cytokines (IL-6, IL-1\u0026beta;, and TNF-\u0026alpha;) and spike protein levels compared with non-infected cells. (Figure. 4A and B). In contrast, apigetrin attenuated the PSCV-induced increase in inflammatory cytokines and spike protein levels (Figure. 4A and B). IL-6, IL-1\u0026beta;, and TNF-\u0026alpha; secretion levels increased by PSCV in MH-S and THP-1 cells (Figure. 4C-H). The amount showed 129.5 pg/ml for IL-6, 119 pg/ml for IL-1\u0026beta;, and 201 pg/ml for TNF-\u0026alpha; increasing 34.54, 14.4, and 6.19 folds respectively, compared with the control group (3.75, 8.23, and 32.3 pg/ml) in MH-S cells (Figure. 4C, D, and E). Apigetrin reduced the increased IL-6, IL-1\u0026beta;, and TNF-\u0026alpha; secretion levels up to 22.5, 47.3, and 68.2%, respectively (Figure 4C, D, and E). In the case of THP-1 cells, the increased amount indicated 93.9, 77.29, and 156 pg/ml for IL-6, IL-1\u0026beta;, and TNF-\u0026alpha;, rising 14, 6.08, and 5.71 folds by PSCV, respectively, compared with the control group (6.7, 12.7, and 27.3 pg/ml) (Figure. 4F, G, and H). Similar to MH-S cell data, apigetrin decreased the increased secretion levels of cytokines up to 71, 56.6, and 67.2% for IL6, IL-1\u0026beta;, and TNF-\u0026alpha;, respectively (Figure 4F, G, and H).\u003c/p\u003e\n\u003cp\u003e3.6. Apigetrin attenuated MRC-5 cell proliferation, migration, and expression of CTGF, COLA1, \u0026alpha;-SMA, and HIF-1\u0026alpha; induced by conditioned medium from PSCV-treated MH-S or THP-1 cells (CMPSCV).\u003c/p\u003e\n\u003cp\u003eThe effect of apigetrin on PSCV-induced PF was evaluated in CMPSCV-induced MRC-5 cells. Apigetrin reduced the MRC-5 cell proliferation by 18% CMPSCV of MH-S and THP-1 cells enhanced (Figure. 5A and D). Transwells were used to assess the dynamic fibroblast migration in PF. CMPSCV of MH-S or THP-1 cells increased MRC-5 cell migration by 88 and 87%, respectively, compared to non-treated cells (Figure. 5B and E). The increase in MRC-5 cell motility by CMPSCV was suppressed by apigetrin by 65% and 58%, respectively. Apigetrin significantly decreased the increased CTGF, COLA1, \u0026alpha;-SMA, and HIF-1\u0026alpha; expression by CMPSCV (Figure 5C and F). Picro Sirius red staining was used to assess collagen expression and observe the differentiated phenotype of MRC-5 cells in response to CMPSV. As shown in Figure. 5B and E, CMPSCV in MH-S or THP-1 cells induced long and stiff-type cells and darker MRC-5 cells. Apigetrin induced a shorter and lighter cell morphology than CMPSCV-induced MRC-5 cells (Figure 5B and E).\u003c/p\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eIn this study, we focused on SARS-CoV-2 post-infection complications and established \u003cem\u003ein vitro\u003c/em\u003e models to mimic SARS-CoV-2 infection-related complications. Many studies have reported on the development of SARS-CoV-2 vaccines and drugs that block entry into cells to prevent SARS-CoV-2 infection. According to recently reported clinical data, ACE2 inhibitors and angiotensin receptor blockers (ARBs), the leading SARS-CoV-2 treatments, have not improved clinical outcomes in adult patients with severe COVID-19 and may even worsen them [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. The renin-angiotensin system (RAS) relates to SARS-CoV-2 infection, ARDS, pulmonary hypertension, and PF [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e, \u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e] RAS system comprises two pathways. One is the angiotensin II (Ang II) generation from angiotensinogen by the enzymes renin and ACE. Ang II binds to the angiotensin type 1 receptor (AT1R) to cause tissue in-jury such as pulmonary hypertension and fibrosis. Another pathway involves the degradation of Ang II to angiotensin 1\u0026ndash;7 by the enzyme ACE2, which protects against tissue damage. Therefore, ACE2 plays a counterregulatory role in inhibiting the RAS by removing Ang II. ACE2 has been reported to prevent the development of severe acute respiratory syndrome in SARS-CoV infection [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e] and protect against severe acute lung failure [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e], it has been reported that ACE2 plays a functional receptor on cell surfaces through which SARS-CoV-2 enters host cells [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. In summary, ACE2 is a double-edged sword. There-fore, these targeted inhibitors appear to be suitable for the early or preventive treatment of SARS-CoV-2. ARDS and PF are serious SARS-CoV-2 infection complications. Investigating immunomodulatory therapies is essential, as an overactive immune response (cytokine storm) has been implicated in severe COVID-19 cases. Targeting inflammation and immune responses may help manage post-SARS-CoV-2 complications. To date, the well-known drugs for SARS-CoV-2 immune hyperactivity include tyrosine kinase inhibitors of JAK-STAT signaling and glucocorticoids. Although dexamethasone and methylprednisolone are effective glucocorticoids in reducing the severity of COVID-19 and associated comorbidities such as chronic obstructive pulmonary diseases [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e], these glucocorticoid drugs represent a double-edged sword in COVID-19 therapy. The long-term use of high-dose glucocorticoids causes numerous side effects, such as fluid retention, weight gain, and hyperglycemia [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e]. JAK inhibitors have been clinically used to treat several inflammatory and autoimmune diseases [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]. Therefore, JAK inhibitors have been proposed as pharmacological therapies for COVID-19. Tofacitinib, imatinib, and baricitinib exerted clinical benefits in hospitalized patients with COVID-19; however, further studies are required to validate these findings.\u003c/p\u003e \u003cp\u003eImmunological dysregulation, also known as the \u0026ldquo;cytokine storm\u0026rdquo; by SARS-CoV-2, may be a significant contributor to multiorgan dysfunction [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. Many cytokines have been reported at elevated levels in COVID-19 cases, including IL1-β, IL-6, IL-7, IL-8, TGF-β and TNF-α. Elevated pro-inflammatory cytokines contribute to COVID-19-related complications such as ARDS or PF, mediating the initiation and progression of fibrosis and remodeling [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e, \u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]. Based on these studies, we generated \u003cem\u003ein vitro\u003c/em\u003e ARDS and PF models to mimic SARS-CoV-2 complications using pseudo-SARS-CoV-2 in MH-S, THP-1, and MRC-5 cells. Therefore, developing reliable and convenient \u003cem\u003ein vitro\u003c/em\u003e models is a valuable approach. These models enable researchers to study disease mechanisms and test potential therapeutic agents in a controlled environment. Using pseudotyped SARS-CoV-2 can help simulate viral infections without the need for a high-containment BSL-3 laboratory, making it more accessible for research. To ensure that our \u003cem\u003ein vitro\u003c/em\u003e model closely mimics the clinical aspects of post-SARS-CoV-2 complications, we checked the proinflammatory cytokines, PF-related markers, and HIF-1α levels that have been reported as highly expressed in SARS-CoV-2 patients in PSCV- exposure MH-S and THP-1 cells or CPMSCV-cultured MRC-5 cells. As shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA and B, IL-6, IL-1β, TNF-α, and HIF-1α showed higher expression than PSCV-non-treated cells in MH-S and THP-1 cells. A conditioned medium of PSCV-treated MH-S or THP-1 cells (CMPSV) in MRC-5 cells shows increased CTGF, COLA1, α-SMA, and HIF-1α expressions in Figs.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC and D.\u003c/p\u003e \u003cp\u003eHIF-1α is recognized as a significant activator in glycolysis and is also implicated in inflammatory responses. This suggests that HIF-1α may play a role in the pathogenesis of COVID-19 [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. A recent paper has reported that the HIF-1α mRNA level is much higher in PBMCs of COVID-19 inflammatory patients related to healthy individuals [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Also, the contribution of hypoxia and HIF-1α to the development of interstitial PF as well as PF caused by SARS-CoV-2 is already known [\u003cspan additionalcitationids=\"CR42 CR43\" citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. Consistent with other reported COVID-19 clinical data, HIF-1α levels increased in PSCV-infected MH-S and THP-1 cells, as well as in CMPSV-stimulated MRC-5 cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). In contrast, HIF-1α knockdown was shown to ameliorate inflammation induced by PSCV infection in MH-S and THP-1 cells and decrease increased CTGF, COLA1, and α-SMA in CPMSCV-exposure MRC-5 cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA, B, E, and F). Cobalt chloride (CoCl\u003csub\u003e2\u003c/sub\u003e), a hypoxia mimic, increased or maintained the cytokine levels induced by PSCV in MH-S and THP-1 cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC and D).\u003c/p\u003e \u003cp\u003eOn the contrary, recently, starting with epidemiological reports for lower COVID-19 incidence in populations living at high altitudes, a few studies supporting the epidemiological reports interestingly showed that an association of the rs11549465 variant of HIF-α with COVID-19 susceptibility was recently discovered [\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e] and hypoxic and pharmaco-logical drug of HIF inhibit the infection of lung cells by SARS-CoV-2 by reducing ACE2 viral receptor expression [\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e]. However, while these studies are sufficient to help us understand the molecular mechanisms behind the lower incidence of COVID-19 in high-altitude populations, they do not help explain \u0026ldquo;happy hypoxia,\u0026rdquo; a pathophysiological phenomenon in which hypoxia increases a patient\u0026rsquo;s risk of developing a severe form of COVID-19 [\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e]. Methods for targeting ACE2 can induce the possible dysfunction of signals when ACE2 is reduced, makes Ang(1\u0026ndash;7) no longer synthesized, and AngII accumulates and binds AT1R, leading to HIF-1α causing tissue injury [\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e, \u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e]. This is also why SARS-CoV-2 binds to ACE2, allowing it to enter cells and cause more severe disease. Furthermore, in the recently reported study by Peter A.C. Wing et al., hypoxia and FG-4592 increased ACE, but the expression of mRNA for HIF-1alpha, a known hypoxia marker, was reduced in these treated cells than in normoxia, 18% O\u003csub\u003e2\u003c/sub\u003e levels [\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e]. Unlike the recently reported study by Peter A.C. Wing et al., it has been reported that hypoxia increases ACE, ACE2, and HIF-1α expression in pulmonary artery smooth muscle cells (PASMCs) [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e] and pulmonary artery adventitial fibroblasts (FBPA) [\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e], and HIF-1siRNA decreases ACE expression and keeps ACE2 expression in normoxic-PASMCs [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. CoCl2, a hypoxia mimic, maintained or induced spike protein expression in PSCV-stimulated MH-S and THP-1 cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC and D). However, HIF-1 siRNA reduces spike protein expression in PSC-stimulated MH-S and THP-1 cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA and B).\u003c/p\u003e \u003cp\u003eIn this study, the effects of apigetrin were evaluated using the SARS-CoV-2 complication mimic \u003cem\u003ein vitro\u003c/em\u003e model. First, apigetrin was shown to block the activity between the binding spike S RBD and ACE2 receptor and to decrease spike protein expression (Figure. 3A and B). These results in apigetrin attenuated increase of inflammatory cytokine (IL-6, IL-1β, and TNF-α) levels on cytosol, and secretion by PSCV in MH-S and THP-1 cells (Figure. 4). Consistent with our data, apigetrin has been reported to lower TNF-α, IL-1β, and IL-6 production and mRNA expression in LPS-stimulated various cells [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e] and in mice with acute otitis media [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Similarly to our model, it has been reported that apigetrin inhibits IL-1α and TGF-β production induced by recombinant spike protein of SARS-CoV-2-stimulated RAW 264.7 cells [\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e]. Furthermore, apigetrin has been reported to possess potential inhibitory activity against SARS-CoV-2 3-chymotrypsin-like protease (main protease, Mpro) controlling this COVID-19 virus replication and is essential for its life cycle, according to computational analysis, including molecular docking and pharmacokinetic studies [\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e]. In this study, apigetrin is shown to attenuate MRC-5 cell proliferation, migration, expression of CTGF, COLA1, α-SMA, and HIF-1α induced by conditioned medium from PSCV-treated MH-S or THP-1 cells (CMPSCV) (Figure. 5).\u003c/p\u003e"},{"header":"5. Conclusions","content":"\u003cp\u003eIn summary, in this study, we evaluated the feasibility of an in vitro model of SARS-CoV-2 sequelae mimicking and used it to identify molecular mechanisms for HIF-1α targeting in SARS-CoV-2-associated diseases. Furthermore, apigetrin, a candidate drug for treating SARS-CoV-2 complications, was evaluated in this \u003cem\u003ein vitro\u003c/em\u003e model. The PSCV particles treated MH-S and THP-1 cells showed increased expression of proinflammatory cytokines (IL-6, IL-1β, and TNF-α) and HIF-1α, consistent with other profiling data in SARS-CoV-2-infected patients have been reported. HIF-1α knockdown was used to determine the role of HIF-1α in this model, with HIF-1α knockdown decreasing increased proinflammatory cytokines levels and fibrosis-related protein levels in PSCV-stimulated MH-S and THP-1 cells and CMPSCV-cultured MRC-5 cells. Apigetrin inhibits the binding of the SARS-CoV-2 spike protein RBD to ACE2 SARS. Increased proinflammatory cytokines, HIF-1α, and spike protein levels were decreased by apigetrin in the SARS-CoV-2 ARDS mimic \u003cem\u003ein vitro\u003c/em\u003e model. Apigetrin suppressed the increase of cell growth, migration, collagen synthesis, and fibrosis-regulatory proteins (CTGF, COLA1, α-SMA, and HIF-1α) in the PF model, CMPSCV-cultured MRC-5 cells. Thus, our data support that HIF-1α might be a novel target for SARS-CoV-2 sequela therapies, and apigetrin, a representative HIF-1α inhibitor, would have a potential value in regulating SARS-CoV-2 related diseases.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT) (No. NRF-2021R1A2C2009095)\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflict of interest/Competing interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare no conflict or competing interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMaterials availability\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCode availability\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contribution\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eH.-J.L.; methodology, project administration, supervision, writing\u0026mdash;original draft preparation; H.H. and J.-E.K.; validation, investigation, data curation, and software. All the authors have read and agreed to the published version of the manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eabcam. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.abcam.com/products?sortOptions=Relevance\u0026amp;keywords=picrosirius+red\u003c/span\u003e\u003cspan address=\"https://www.abcam.com/products?sortOptions=Relevance\u0026amp;keywords=picrosirius+red\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWorld Health Organization. Coronavirus disease (COVID-19). 2023; Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.who.int/health-topics/coronavirus#tab=tab_1\u003c/span\u003e\u003cspan address=\"https://www.who.int/health-topics/coronavirus#tab=tab_1\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYe Q, Wang B, Mao J. Cytokine storm in COVID-19 and treatment. J Infect. 2020;80(6):607\u0026ndash;13.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGrasselli G, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome\u0026ndash;Authors' reply. Lancet Respiratory Med. 2021;9(1):e5\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFara A, et al. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open biology. 2020;10(9):200160.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUkwenya VO, et al. The Impact of Deranged Glucose Metabolism and Diabetes in the Pathogenesis and Prognosis of the Novel SARS-CoV-2: A Systematic Review of Literature. Curr Diabetes Rev. 2022;18(3):101\u0026ndash;12.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTaniguchi-Ponciano K, et al. Increased expression of hypoxia-induced factor 1α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients. Ann Med. 2021;53(1):197\u0026ndash;207.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTian M, et al. HIF-1α promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19. Signal Transduct Target Therapy. 2021;6(1):308.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAllen SP, et al. Transcriptomic analysis of human astrocytes in vitro reveals hypoxia-induced mitochondrial dysfunction, modulation of metabolism, and dysregulation of the immune response. Int J Mol Sci. 2020;21(21):8028.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eM\u0026eacute;n\u0026eacute;gaut L et al. Interplay between liver X receptor and hypoxia inducible factor 1α potentiates interleukin-1β production in human macrophages. Cell Rep, 2020. 31(7).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu J, et al. CCR7 chemokine receptor-inducible lnc-Dpf3 restrains dendritic cell migration by inhibiting HIF-1α-mediated glycolysis. Immunity. 2019;50(3):600\u0026ndash;15. e15.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJahani M, Dokaneheifard S, Mansouri K. Hypoxia: A key feature of COVID-19 launching activation of HIF-1 and cytokine storm. J Inflamm. 2020;17(1):1\u0026ndash;10.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCodo AC, et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis. Cell Metabol. 2020;32(3):437\u0026ndash;46. e5.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePearce L, Davidson SM, Yellon DM. The cytokine storm of COVID-19: a spotlight on prevention and protection. Expert Opin Ther Targets. 2020;24(8):723\u0026ndash;30.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYavuz S, \u0026Uuml;nal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020;50(9):611\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLim H-S, et al. Apigetrin from Scutellaria baicalensis Georgi inhibits neuroinflammation in BV-2 microglia and exerts neuroprotective effect in HT22 hippocampal cells. J Med Food. 2016;19(11):1032\u0026ndash;40.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHadrich F, Sayadi S. Apigetrin inhibits adipogenesis in 3T3-L1 cells by downregulating PPARγ and CEBP-α. Lipids Health Dis. 2018;17:1\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKim SM, et al. Apigetrin induces extrinsic apoptosis, autophagy and G2/M phase cell cycle arrest through PI3K/AKT/mTOR pathway in AGS human gastric cancer cell. J Nutr Biochem. 2020;83:108427.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGuo H, Li M, Xu L-J. Apigetrin treatment attenuates LPS-induced acute otitis media though suppressing inflammation and oxidative stress. Biomed Pharmacother. 2019;109:1978\u0026ndash;87.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSun Q, Lu N-N, Feng L. Apigetrin inhibits gastric cancer progression through inducing apoptosis and regulating ROS-modulated STAT3/JAK2 pathway. Biochem Biophys Res Commun. 2018;498(1):164\u0026ndash;70.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee Y-K, et al. AKT, a Key Transmitter of HIF-1α and AR Signaling Pathways, Has a Critical Role in the Apigetrin-Mediated Anti-Cancer Effects in Prostate Cancer Cells. Biomedicines. 2022;10(6):1370.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAmin BJH, et al. Post COVID-19 pulmonary fibrosis; a meta-analysis study. Annals Med Surg. 2022;77:103590.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZheng Z, Peng F, Zhou Y. \u003cem\u003ePulmonary fibrosis: A short-or long-term sequelae of severe COVID-19?\u003c/em\u003e Chinese Medical Journal-Pulmonary and Critical Care Medicine, 2023.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMylvaganam RJ et al. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. Eur respiratory Rev, 2021. 30(162).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKramer D, Hilton R, Roman J. Pulmonary fibrosis and COVID-19. The American Journal of the Medical Sciences; 2023.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFlorescu S, et al. Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support\u0026ndash;free days in patients hospitalized with COVID-19: a randomized clinical trial. JAMA. 2023;329(14):1183\u0026ndash;96.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang R, et al. Role of HIF-1α in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. Am J Physiology-Lung Cell Mol Physiol. 2009;297(4):L631\u0026ndash;40.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePang J, et al. Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment. Obes Med. 2021;22:100312.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKuba K, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus\u0026ndash;induced lung injury. Nat Med. 2005;11(8):875\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eImai Y, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi W, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450\u0026ndash;4.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTai W, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17(6):613\u0026ndash;20.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEl-Saber Batiha G, et al. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology. 2022;30(4):1189\u0026ndash;205.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYang R, Yu Y. Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers. Int J Biol Sci. 2021;17(6):1530.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCiechanowicz P, et al. JAK-inhibitors in dermatology: current evidence and future applications. J Dermatological Treat. 2019;30(7):648\u0026ndash;58.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJamilloux Y, et al. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun rev. 2019;18(11):102390.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCostela-Ruiz VJ, et al. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62\u0026ndash;75.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSun X, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38\u0026ndash;42.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcElvaney OJ, et al. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med. 2020;202(6):812\u0026ndash;21.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNalbandian A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601\u0026ndash;15.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTzouvelekis A, et al. Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1α in disease pathogenesis. Am J Respir Crit Care Med. 2007;176(11):1108\u0026ndash;19.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHiggins DF, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Investig. 2007;117(12):3810\u0026ndash;20.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eManresa MC, Godson C, Taylor CT. Hypoxia-sensitive pathways in inflammation-driven fibrosis. Am J Physiology-Regulatory Integr Comp Physiol. 2014;307(12):R1369\u0026ndash;80.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen J-Y, et al. Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis. Chin Med J. 2020;133(12):1390\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDas A, Patra M, Dhangadamajhi G. Association of rs11549465 (C1772T) variant of hypoxia-inducible factor-1α with Covid-19 susceptibility. A population-based epidemiological study. Hum Cell. 2021;34(6):1937\u0026ndash;40.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWing PA et al. Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells. Cell Rep, 2021. 35(3).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGani M, et al. Possible silent hypoxemia in a COVID-19 patient: a case report. Annals Med Surg. 2020;60:583\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRysz S, et al. COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system. Nat Commun. 2021;12(1):2417.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDevaux CA, Raoult D. The impact of COVID-19 on populations living at high altitude: Role of hypoxia-inducible factors (HIFs) signaling pathway in SARS-CoV-2 infection and replication. Front Physiol. 2022;13:960308.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKrick S, et al. Hypoxia-driven proliferation of human pulmonary artery fibroblasts: cross‐talk between HIF‐1α and an autocrine angiotensin system. FASEB J. 2005;19(7):1\u0026ndash;26.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHa S-E, et al. Apigetrin Abrogates Lipopolysaccharide-Induced Inflammation in L6 Skeletal Muscle Cells through NF-κB/MAPK Signaling Pathways. Curr Issues Mol Biol. 2022;44(6):2635\u0026ndash;45.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLuo G, Zhu W. Apigetrin inhibits cytotoxicity and dysregulation of ACE2, IL1α and TGFβ expression induced by recombinant spike protein of SARS-CoV-2. World J Adv Res Reviews. 2021;9(2):144\u0026ndash;54.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eManokaran S et al. Molecular docking and pharmacokinetic studies of naturally occurring flavonoid glycosides and their activity against COVID-19 viral proteins. SPAST Abstracts, 2021. 1(01).\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"SARS-CoV-2, Acute respiratory distress syndrome (ARDS), Pulmonary fibrosis (PF), Hypoxia-inducible factor-1α (HIF-1α), Apigetrin","lastPublishedDoi":"10.21203/rs.3.rs-4131121/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4131121/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eSARS-CoV-2 has become a global public health problem. Acute respiratory distress syndrome (ARDS) is the leading cause of death due to the SARS-CoV-2 infection. Pulmonary fibrosis (PF) is a severe and frequently reported COVID-19 sequela. In this study, an \u003cem\u003ein vitro\u003c/em\u003e model of ARDS and PF caused by SARS-CoV-2 was established in MH-S, THP-1, and MRC-5 cells using pseudo-SARS-CoV-2 (PSCV). Expression of proinflammatory cytokines (IL-6, IL-1β, and TNF-α) and HIF-1α was increased in PSCV-infected MH-S and THP-1 cells, ARDS model, consistent with other profiling data in SARS-CoV-2-infected patients have been reported. Hypoxia-inducible factor-1 alpha (HIF-1α) siRNA and cobalt chloride were tested using this \u003cem\u003ein vitro\u003c/em\u003e model. Furthermore, apigetrin, a glycoside bioactive dietary flavonoid derived from several plants, including Crataegus pinnatifida, which is reported to be a HIF-1α inhibitor, was tested in this \u003cem\u003ein vitro\u003c/em\u003e model [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Apigetrin significantly reduced the increased inflammatory cytokine (IL-6, IL-1β, and TNF-α) expression and secretion by PSCV in MH-S and THP-1 cells. Apigetrin inhibited the binding of the SARS-CoV-2 spike protein RBD to the ACE2 protein. An \u003cem\u003ein vitro\u003c/em\u003e model of PF induced by SARS-CoV-2 was produced using a conditioned medium of THP-1 and MH-S cells that were PSCV-infected (CMPSCV) into MRC-5 cells. In a PF model, CMPSCV treatment of THP-1 and MH-S cells increased cell growth, migration, and collagen synthesis in MRC-5 cells. In contrast, apigetrin suppressed the increase in cell growth, migration, and collagen synthesis induced by CMPSCV in THP-1 and MH-S MRC-5 cells. Also, compared to control, fibrosis-related proteins (CTGF, COLA1, α-SMA, and HIF-1α) levels were over two-fold higher in CMPSV-treated MRC-5 cells. Apigetrin decreased protein levels in CMPSCV-treated MRC-5 cells. Thus, our data suggest that hypoxia-inducible factor-1 alpha (HIF-1α) might be a novel target for SARS-CoV-2 sequela therapies and apigetrin, representative of HIF-1alpha inhibitor, exerts anti-inflammatory and PF effects in PSCV-treated MH-S, THP-1, and CMPVSC-treated MRC-5 cells. These findings indicate that HIF-1α inhibition and apigetrin would have a potential value in controlling SARS-CoV-2-related diseases.\u003c/p\u003e","manuscriptTitle":"Effect of apigetrin in pseudo-SARS-CoV-2-induced inflammatory and pulmonary fibrosis in vitro model","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-03-25 18:04:25","doi":"10.21203/rs.3.rs-4131121/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"8171f7de-97a3-494d-8b95-9885afcb6628","owner":[],"postedDate":"March 25th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-04-04T16:30:21+00:00","versionOfRecord":[],"versionCreatedAt":"2024-03-25 18:04:25","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4131121","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4131121","identity":"rs-4131121","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}